Title | The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Barish, Grant D., Yu Ruth T., Karunasiri Malith S., Becerra Diana, Kim Jason, Tseng Tiffany W., Tai Li-Jung, Leblanc Matthias, Diehl Cody, Cerchietti Leandro, Miller Yury I., Witztum Joseph L., Melnick Ari M., Dent Alexander L., Tangirala Rajendra K., and Evans Ronald M. |
Journal | Cell Metab |
Volume | 15 |
Issue | 4 |
Pagination | 554-62 |
Date Published | 2012 Apr 04 |
ISSN | 1932-7420 |
Keywords | Animals, Atherosclerosis, Base Sequence, Bone Marrow, Cholesterol, DNA-Binding Proteins, Gene Expression Regulation, Inflammation, Lipoproteins, LDL, Macrophages, Male, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Receptor Co-Repressor 2, Proto-Oncogene Proteins c-bcl-6, Tendinopathy |
Abstract | <p>Chronic inflammation is a hallmark of atherosclerosis, but its transcriptional underpinnings are poorly understood. We show that the transcriptional repressor Bcl6 is an anti-inflammatory regulator whose loss in bone marrow of Ldlr(-/-) mice results in severe atherosclerosis and xanthomatous tendonitis, a virtually pathognomonic complication in patients with familial hypercholesterolemia. Disruption of the interaction between Bcl6 and SMRT or NCoR with a peptide inhibitor in vitro recapitulated atherogenic gene changes in mice transplanted with Bcl6-deficient bone marrow, pointing to these cofactors as key mediators of Bcl6 inflammatory suppression. Using ChIP-seq, we reveal the SMRT and NCoR corepressor cistromes, each consisting of over 30,000 binding sites with a nearly 50% overlap. While the complete cistromes identify a diversity of signaling pathways, the Bcl6-bound subcistromes for each corepressor are highly enriched for NF-κB-driven inflammatory and tissue remodeling genes. These results reveal that Bcl6-SMRT/NCoR complexes constrain immune responses and contribute to the prevention of atherosclerosis.</p> |
DOI | 10.1016/j.cmet.2012.02.012 |
Alternate Journal | Cell Metab |
PubMed ID | 22465074 |
PubMed Central ID | PMC3367511 |
Grant List | P01 HL088093 / HL / NHLBI NIH HHS / United States R37DK057978 / DK / NIDDK NIH HHS / United States R01 HD027183 / HD / NICHD NIH HHS / United States U19DK062434 / DK / NIDDK NIH HHS / United States P30 DK063491 / DK / NIDDK NIH HHS / United States P30DK063491 / DK / NIDDK NIH HHS / United States R37 DK057978 / DK / NIDDK NIH HHS / United States R01 HL086566 / HL / NHLBI NIH HHS / United States R01HD027183 / HD / NICHD NIH HHS / United States R01 CA104348 / CA / NCI NIH HHS / United States / HHMI_ / Howard Hughes Medical Institute / United States P30 CA014195 / CA / NCI NIH HHS / United States K08HL092298 / HL / NHLBI NIH HHS / United States K08 HL092298 / HL / NHLBI NIH HHS / United States U19 DK062434 / DK / NIDDK NIH HHS / United States P01HL088093 / HL / NHLBI NIH HHS / United States CA014195-38 / CA / NCI NIH HHS / United States R01HL086566 / HL / NHLBI NIH HHS / United States |